1,488 reports of this reaction
3.2% of all EMTRICITABINE AND TENOFOVIR ALAFENAMIDE reports
#15 most reported adverse reaction
OSTEOPENIA is the #15 most commonly reported adverse reaction for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, manufactured by Gilead Sciences, Inc.. There are 1,488 FDA adverse event reports linking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE to OSTEOPENIA. This represents approximately 3.2% of all 46,639 adverse event reports for this drug.
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE has an overall safety score of 85 out of 100. Patients taking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE who experience osteopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OSTEOPENIA is moderately reported among EMTRICITABINE AND TENOFOVIR ALAFENAMIDE users, representing a notable but not dominant share of adverse events.
In addition to osteopenia, the following adverse reactions have been reported for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE:
The following drugs have also been linked to osteopenia in FDA adverse event reports:
OSTEOPENIA has been reported as an adverse event in 1,488 FDA reports for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OSTEOPENIA accounts for approximately 3.2% of all adverse event reports for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, making it a notable side effect.
If you experience osteopenia while taking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.